StockData

Abeona Therapeutics vs Rocket Pharmaceuticals

ABEO and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABEO and RCKT compare

Rocket Pharmaceuticals is the larger company, worth 1.6 times as much as Abeona Therapeutics ($232M against $149M).

Abeona Therapeutics scores higher on the StockData Score (8 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABEORCKT
Size and price
Market cap$149M$232M
Share price$2.60$2.11
Change, 1 year−41.6%−30.8%
Change, 5 years−85.8%−91.1%
Beta (5Y)1.712.32
Employees226202
StockData Score
Total score8 (better)3
Valuation score3 (better)1
Growth score1 (better)0
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/S5.8×–
P/B1.2×0.6× (better)
FCF yield−54.8% (better)−73.6%
Fair value$3.58–
Margin of safety27.4%–
Growth
Revenue growth, 5Y average−10.3%–
Net income growth (TTM)−210%–
Profitability
Gross margin67.1%–
Operating margin−328%–
Net margin−246%–
FCF margin−319%–
Return on equity−43.1%−4.8% (better)
Return on invested capital–−180%
Financial health
Debt / equity0.12–
Interest coverage−25.3× (better)−101.3×
Current ratio6.639.24 (better)
Altman Z-score−4.80−2.72 (better)
Piotroski F-score4 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions77.9%90.9%
Held by insiders12.3%22.3%
Insider net buying, 12 months−$3.5M−$934K (better)
Short interest, % of float33.7%19.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.